Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3BNC117-LS and 10-1074-LS in People Living With HIV on Suppressive ART
NCT05612178Phase 1Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2023
- Primary completion
- Mar 2027
- Modality
- Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing 3BNC117-LS and 10-1074-LS with Placebo (2 arms). Primary endpoint: Solicited and unsolicited grade 3 or higher adverse events. Started Jul 2023; status: active, not recruiting.
02
Drugs
Teropavimabzinlirvimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05612178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05612178.